Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: testing Placebo for Hip Osteoarthritis

Surgical trauma induces activation of the sympathetic nervous system and triggers a systemic inflammatory response that may adversely affect postoperative recovery. Dexmedetomidine, a highly selective α2-adrenoceptor agonist, has been proposed as a pharmacological neuromodulatory strategy capable of attenuating sympathetic activation and modulating neuroimmune interactions during the perioperative period.

Official registry: https://clinicaltrials.gov/study/NCT07743853 · Poznan University of Medical Sciences · enrollment listed as 90

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Placebo, Dexmedetomidine, or Dexmedetomidine. The registry lists allocation as randomized. Surgical trauma induces activation of the sympathetic nervous system and triggers a systemic inflammatory response that may adversely affect postoperative recovery.

They plan to enroll about 90 people at Poznan. Taking part typically means taking a study drug (or dummy pill) plus check-ins.

Official title (unrewritten)

Intravenous Dexmedetomidine as a Perioperative Autonomic-Immune Neuromodulator in Total Hip Arthroplasty: a Randomized Double-Blind Trial

Interventions: Placebo, Dexmedetomidine, Dexmedetomidine

Primary outcome (registry wording): Change in the Systemic Immune-Inflammation Index (SII)

Who it is for (from inclusion criteria)

  • Ages 50 Years to 90 Years
  • Adults aged 50-90 years
  • Scheduled for elective primary total hip arthroplasty due to primary hip osteoarthritis
  • American Society of Anesthesiologists (ASA) physical status I-III
  • Planned spinal anesthesia combined with ultrasound-guided Pericapsular Nerve Group (PENG) block

Public study contact (from the registry)

MAlgorzata Reysner, MD PhD

+48 61 8310122

mreysner@ump.edu.pl

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingNot a traditional drug phaseClermont-Ferrand
Not a traditional drug phase: Development of a screening algorithm designed to determine a "dysmobility" profile in patients with chronic illness. for Joint Osteoarthritis

Chronic illness is a public health issue and mobility loss is frequent in this population. Among its' multiple physical and psychological consequences, increased mortality and cardiovascular morbidity seem the main concern.

NCT04375280 · Official ClinicalTrials.gov record · University Hospital, Clermont-Ferrand

RecruitingNot a traditional drug phaseHelsinki
Not a traditional drug phase: Trapeziectomy for Thumb Osteoarthritis

A multi-center randomly assigned compared with a dummy treatment clinical trial which determines the how well it works of trapeziectomy in patients with persistent painful osteoarthritis at the base of the thumb. The primary outcome is patient reported evaluation of pain and function of the wrist and hand at 6 months after the randomization to treatment group.

NCT05127005 · Official ClinicalTrials.gov record · Tampere University Hospital

FAQ about this NCT record

Is NCT07743853 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07743853?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07743853?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary